Wegovy vs. Mounjaro
Wegovy and Mounjaro differ in their mechanisms and approvals. Wegovy is a GLP-1 receptor agonist approved for chronic weight management, while Mounjaro, a dual GIP and GLP-1 agonist, is primarily for type 2 diabetes. Wegovy excels in weight loss (approximately 15% of bodyweight), whereas Mounjaro shows superior HbA1c reductions and promising weight benefits. Wegovy lacks off-label uses, but Mounjaro is also used for weight management. Both have similar side effects like nausea, but Mounjaro has a higher risk of thyroid tumors. Cost-wise, Wegovy is slightly more expensive at $1,375/month compared to Mounjaro's $1,135/month. Neither drug faces shortages.
Slows gastric emptying, reduces appetite, and enhances feelings of fullness, leading to lower calorie intake. It also stimulates insulin release and reduces glucagon secretion, improving blood sugar control.
Common Side Effects
Nausea, vomiting, diarrhea, constipation, abdominal pain, headache, and fatigue.
Serious Potential Side Effects
Pancreatitis, gallbladder issues, kidney problems, and increased heart rate, thyroid cancer, anaphylaxis (or serious allergic reactions)
Enhances the effects of both incretin hormones. GIP improves insulin sensitivity and enhances fat metabolism, while GLP-1 reduces appetite, delays gastric emptying, and promotes insulin secretion, making it effective for blood sugar control and weight loss.
Common Side Effects
Nausea, vomiting, diarrhea, decreased appetite, and indigestion
Serious Potential Side Effects
Pancreatitis, thyroid tumors (potential risk), gallbladder issues, kidney problems, and serious allergic reactions